Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial

Melanie J. Davies (Lead / Corresponding author), David Russell-Jones, Thomas M. Barber, Fernando J. Lavalle-González, Gagik R. Galstyan, Dhalong Zhu, Mike Baxter, Cecile Dessapt-Baradez, Rory J. McCrimmon

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)
    26 Downloads (Pure)

    Fingerprint Dive into the research topics of 'Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences